Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC
Status:
Not yet recruiting
Trial end date:
2028-04-04
Target enrollment:
Participant gender:
Summary
Veterans with advanced lung cancer may benefit from recent advances in technologies that is
designed to change the activities of their own white blood cells and help kill tumors.
However, many cancers can hide from white blood cells making white blood cells less effective
in killing tumors. In this study the investigators plan to boost the activity of patients
white blood cell by making tumor cells more visible to the white blood cells. This will be
done by injecting antibodies and a new drug that together can make white blood cells inside
tumors more active. The investigators plan to recruit sixteen people with advanced lung
cancer to make sure that this treatment, which has not been done in any humans, is safe and
well tolerated.